ARCH Venture Partners Founded 1986
Founders Clinton Bybee Keith Crandell Robert Nelsen Steven Lazarus
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 126
Average round size
info
The average size of a deal this fund participated in
$36M
Portfolio companies 126
Rounds per year 3.60
Lead investments 41
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.51
Exits -
Key employees -
Stages of investment
Early Stage Venture
Seed
Venture
Areas of investment
Biotechnology
Health Diagnostics
Life Science
Pharmaceutical
Therapeutics
Venture Capital
Summary

In 1986 was created ARCH Venture Partners, which is appeared as VC. The leading representative office of defined VC is situated in the Chicago. The venture was found in North America in United States.

The fund was created by Clinton W. Bybee, Keith L. Crandell, Robert Nelsen, Steven Lazarus. We also calculated 6 valuable employees in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the ARCH Venture Partners, startups are often financed by Lux Capital, In-Q-Tel, Alexandria Real Estate Equities. The meaningful sponsors for the fund in investment in the same round are Wellcome Trust, Third Rock Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by Wellcome Trust, Versant Ventures, Lux Capital.

The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Software, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Juno Therapeutics, Receptos, GRAIL Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

The fund is constantly included in 7-12 investment rounds annually. The higher amount of exits for fund were in 2015. When the investment is from ARCH Venture Partners the average startup value is 50-100 millions dollars. This ARCH Venture Partners works on 7 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies.

Read more
Latest deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
EQRx
Biotechnology
Health Care
Medical
Pharmaceutical
Series B
500M11 Jan 2021 United Kingdom, Cambridge
EQRx
Biotechnology
Health Care
Medical
Pharmaceutical
Series A
200M12 Jan 2020 United Kingdom, Cambridge
Magen BioSciences
Biotechnology
Drug Discovery
Health Care
Pharmaceuticals
Therapeutics
Series A
15M28 Aug 2006 United States, Waltham
Aira
Assistive Technology
Augmented Reality
Computer Vision
Internet
Internet of Things
Social Impact
Software
Seed
790K29 Oct 2015 United States, San Diego
NeurogesX
Biotechnology
Medical
Medical Device
Neuroscience
Series C
35M24 Feb 2004 United States, San Carlos
ProjectGuides.com
Marketplace
Online Portals
Professional Services
Series B
6M19 Apr 2000 United States, Seattle
Qihan Biotech
Biotechnology
Clinical Trials
Health Care
Medical
Medical Device
Series A
7M23 Jul 2018 China, Jianggan District
NeurogesX
Biotechnology
Medical
Medical Device
Neuroscience
Series A
8M01 Jun 2000 United States, San Carlos
Reef Point Systems
Internet
Mobile
Security
Wireless
Venture - Series Unknown
22M16 Feb 2000 Canada, Burlington
NeurogesX
Biotechnology
Medical
Medical Device
Neuroscience
Series B
22M23 Jan 2002 United States, San Carlos
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent ARCH Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: